Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | CETP | P11597 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | GFER | P55789 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6038021 | 0.83 | MAPT (0.57) | L3MBTL1MAPTMEN1KMT2APOLB | |
| SCHEMBL6037916 | 0.81 | GFER (0.55) | L3MBTL1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5282924 | 0.80 | GFER (0.59) | L3MBTL1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6038084 | 0.75 | GFER (0.58) | L3MBTL1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1378043 | 0.75 | HDAC1 (0.72) | L3MBTL1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5281181 | 0.74 | DPP4 (0.49) | ALDH1A1 | |
| SCHEMBL6037984 | 0.74 | MAPT (0.57) | L3MBTL1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5281177 | 0.74 | DPP4 (0.49) | ALDH1A1 | |
| SCHEMBL5282279 | 0.74 | ITGB3 (0.47) | KMT2ALMNAHTT | |
| SCHEMBL1907462 | 0.73 | GRM5 (0.79) | L3MBTL1GRM5MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | L3MBTL1 153/4885GRM5 2981/4885MAPT 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.